Charles River Laboratories International, Inc. (NYSE:CRL) is among the 12 best mid cap AI stocks to buy according to hedge funds. Analyst at TD Cowen raised price target from $197 to $251, suggesting a 38.49% upside. TD Cowen expressed confidence in solid quarterly results and clear insights into the company’s short-term outlook.

Charles River Laboratories International, Inc. (NYSE:CRL) announced a gene therapy collaboration with Gazi University Faculty of Medicine. The collaboration aims to advance research on Hyperphosphatemic tumoral calcinosis (HTC), a rare inherited disorder. The company will provide plasmid DNA for AAV production and support in vitro efficacy studies.

Kerstin Dolph, Corporate Senior Vice President at Charles River, expressed excitement on the collaboration with Gazi University. The partnership aims to transform groundbreaking gene therapy concepts into real-world therapies. Charles River Laboratories International, Inc. provides non-clinical development, drug discovery, and safety testing services globally.

While CRL shows investment potential, some AI stocks offer greater upside with less downside risk. Investors seeking undervalued AI stocks can benefit from a free report on the best short-term AI stock. Charles River Laboratories International, Inc. remains a key player in the non-clinical development and safety testing services sector.

Read more at Yahoo Finance: Analysts Are Bullish On Charles River Laboratories (CRL) Prospects